back to Australia directory
australia clinical guidance

Lipid modification: primary + secondary prevention (statins)

A detailed Australian summary of lipid modification: primary + secondary prevention (statins), with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Use the Australian absolute cardiovascular risk pathway for primary prevention and treat established atherosclerotic disease as secondary prevention. Exclude major secondary dyslipidaemia and record smoking, blood pressure, diabetes, kidney disease, family history and prior medicine intolerance. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:Australian CVD risk guideline

The Bottom Line

  • Use the Australian absolute cardiovascular risk pathway for primary prevention and treat established atherosclerotic disease as secondary prevention.
  • Exclude major secondary dyslipidaemia and record smoking, blood pressure, diabetes, kidney disease, family history and prior medicine intolerance.
  • Repeat a fasting profile when triglycerides are markedly elevated or familial dyslipidaemia classification requires it.
  • Discuss expected absolute benefit, adverse effects, interactions, pregnancy and patient priorities before starting or intensifying lipid-lowering therapy.
sources for this section:Australian CVD risk guideline

Practical clinical workflow

1

Topic-specific assessment action

Use the Australian absolute cardiovascular risk pathway for primary prevention and treat established atherosclerotic disease as secondary prevention.
2

Topic-specific diagnostic action

Discuss expected absolute benefit, adverse effects, interactions, pregnancy and patient priorities before starting or intensifying lipid-lowering therapy.
3

Topic-specific management action

Check adherence and achieved lipid response, then consider additional therapy for persistent high risk or familial hypercholesterolaemia under Australian access rules.
4

Topic-specific follow-through

Use a lower starting intensity and closer review for frailty, significant interactions or previous muscle symptoms, then rechallenge systematically when safe.
sources for this section:Australian CVD risk guideline

Safety boundaries and escalation

  • Urgently assess severe muscle symptoms with weakness, dark urine or systemic illness; pause implicated therapy and check for rhabdomyolysis and kidney injury.
  • Secondary prevention should not be delayed while recalculating primary risk in someone with established atherosclerotic disease.
sources for this section:Australian CVD risk guideline

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:Australian CVD risk guideline

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:Australian CVD risk guideline

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Australian Government Department of Health and Aged CareAustralian Guideline for assessing and managing cardiovascular disease riskISBN 978-1-76007-570-5 路 2023 guideline 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.